Canakinumab (
Ilaris®) is a prescription medication approved to treat rare genetic autoinflammatory conditions known as cryopyrin-associated periodic syndromes (CAPS), such as familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS). It belongs to a group of medicines known as monoclonal antibodies.
Just like any medicine, canakinumab may cause side effects.
However, not everyone who receives the drug will experience problems. In fact, most people tolerate it quite well. If reactions do occur, in most cases, they are minor and either require no treatment or are treated easily by you or your healthcare provider. Serious side effects are less common.
Common side effects seen with canakinumab include but are not limited to:
(Click Canakinumab Side Effects to learn more, including potentially serious side effects you should report immediately to your healthcare provider.)